Uncategorized

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World’s First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

IASO Biotechnology and Innovent Biologics, Inc. announced that China National Medical Products Administration has approved the New Drug Application for FUCASO, the world’s first fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma who received ≥3 lines of prior therapies containing at least one proteasome […]

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World’s First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma Read More »

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Topline results from the TROPION-Lung01 phase 3 trial showed datopotamab deruxtecan demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial Read More »

Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease

Zymedi announced the signing of a clinical Cooperative Research and Development Agreement with the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to develop ZMA001 for the treatment of pulmonary arterial hypertension.

Zymedi announced their collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to develop ZMA001 mAb, a potential treatment for Pulmonary Arterial Hypertension (PAH), a rare, female predominant disease Read More »

Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress

Nicox SA announced that additional data on NCX 470 have been presented at the 10th World Glaucoma Congress (WGC) being held from June 28 to July 1, 2023 in Rome, Italy.

Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress Read More »

Psicología financiera y la influencia de las emociones en la toma de decisiones sobre créditos y préstamos

La psicología financiera es una subdisciplina emergente que intenta comprender cómo nuestras emociones y comportamientos cognitivos influyen en nuestras decisiones financieras. En particular, esta disciplina ha demostrado ser particularmente útil para entender cómo las pe …

Psicología financiera y la influencia de las emociones en la toma de decisiones sobre créditos y préstamos Read More »

Scroll to Top